|
|
Volumn 220, Issue 4, 2015, Pages 581-593.e1
|
|
Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma
a
a
b
c
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B RAF KINASE;
CASPASE 3;
CD8 ANTIGEN;
DABRAFENIB;
EMETIC AGENT;
IPILIMUMAB;
KI 67 ANTIGEN;
MITOGEN ACTIVATED PROTEIN KINASE;
MITOGEN ACTIVATED PROTEIN KINASE KINASE;
TRAMETINIB;
BRAF PROTEIN, HUMAN;
DNA;
IMIDAZOLE DERIVATIVE;
MITOGEN ACTIVATED PROTEIN KINASE KINASE 1;
OXIME;
PYRIDONE DERIVATIVE;
PYRIMIDINONE DERIVATIVE;
TUMOR MARKER;
ACCESSORY NERVE INJURY;
ADULT;
ADVANCED CANCER;
AGED;
APOPTOSIS;
BRAIN HEMORRHAGE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER GRADING;
CANCER GROWTH;
CANCER INHIBITION;
CANCER LOCALIZATION;
CANCER RECURRENCE;
CANCER SIZE;
CANCER STAGING;
CANCER SURGERY;
CANCER SURVIVAL;
CD8+ T LYMPHOCYTE;
CELL PROLIFERATION;
CLINICAL ARTICLE;
CLINICAL OBSERVATION;
CONFERENCE PAPER;
CONTROLLED STUDY;
DEHYDRATION;
DISEASE FREE SURVIVAL;
DRUG ERUPTION;
DRUG WITHDRAWAL;
FATIGUE;
FEMALE;
FEVER;
FOLLOW UP;
GENE MUTATION;
HAND FOOT SYNDROME;
HEART ATRIUM FIBRILLATION;
HUMAN;
HUMAN CELL;
HUMAN TISSUE;
IMMUNE RESPONSE;
INFLAMMATION;
INFLAMMATORY INFILTRATE;
LENGTH OF STAY;
LOW DRUG DOSE;
LYMPH NODE DISSECTION;
LYMPH NODE METASTASIS;
MALE;
MELANOMA;
MOLECULARLY TARGETED THERAPY;
MULTIMODALITY CANCER THERAPY;
MYALGIA;
NAUSEA;
NERVE INJURY;
ONCOLOGICAL PARAMETERS;
OPEN STUDY;
PHASE 2 CLINICAL TRIAL;
POSTOPERATIVE COMPLICATION;
POSTOPERATIVE PERIOD;
PREOPERATIVE PERIOD;
PRIORITY JOURNAL;
SKIN GRAFT;
SOFT TISSUE METASTASIS;
THORACIC NERVE INJURY;
TREATMENT DURATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
TUMOR MICROENVIRONMENT;
VOMITING;
ANTAGONISTS AND INHIBITORS;
BIOPSY;
BIOSYNTHESIS;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG COMBINATION;
DRUG EFFECTS;
FEASIBILITY STUDY;
GENETICS;
METABOLISM;
MIDDLE AGED;
MUTATION;
NUCLEOTIDE SEQUENCE;
ORAL DRUG ADMINISTRATION;
PATHOLOGY;
PREOPERATIVE CARE;
PROCEDURES;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL;
SKIN NEOPLASMS;
YOUNG ADULT;
ADMINISTRATION, ORAL;
ADULT;
AGED;
BIOPSY;
DNA MUTATIONAL ANALYSIS;
DNA, NEOPLASM;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG THERAPY, COMBINATION;
FEASIBILITY STUDIES;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
IMIDAZOLES;
MALE;
MAP KINASE KINASE 1;
MELANOMA;
MIDDLE AGED;
MITOGEN-ACTIVATED PROTEIN KINASES;
MUTATION;
OXIMES;
PREOPERATIVE CARE;
PROSPECTIVE STUDIES;
PROTO-ONCOGENE PROTEINS B-RAF;
PYRIDONES;
PYRIMIDINONES;
SKIN NEOPLASMS;
TUMOR MARKERS, BIOLOGICAL;
YOUNG ADULT;
|
|
EID: 84925645329
PISSN: 10727515
EISSN: 18791190
Source Type: Journal
DOI: 10.1016/j.jamcollsurg.2014.12.057 Document Type: Conference Paper |
|
Times cited : (26)
|
|
References (18)
|
